PMID- 1446958
OWN - NLM
STAT- MEDLINE
DCOM- 19921229
LR  - 20191210
IS  - 0174-4879 (Print)
IS  - 0174-4879 (Linking)
VI  - 30
IP  - 10
DP  - 1992 Oct
TI  - Clinical effect of indolidan in congestive heart failure.
PG  - 405-9
AB  - Indolidan (IN) experimentally inhibits type IV phosphodiesterase. It was 
      administered to twelve patients (age 64 +/- 15 years) with New York Heart 
      Association (NYHA) class 2-3 congestive heart failure in which digoxin and 
      diuretic therapy were continued. IN was administered i.v. at 1,180 +/- 340 
      micrograms (15 micrograms/kg) over two hours. After 24 hours, IN was given p.o. 
      at 231 +/- 44 micrograms. The time course effect of IN i.v. revealed an increase 
      in cardiac index and a decrease in pulmonary capillary wedge pressure and blood 
      pressure. Daily oral administration of IN or placebo was carried out for up to 3 
      months. There were no significant hemodynamic changes of chronically administered 
      IN. The maximum oxygen uptake increased in placebo relative to IN therapy. IN 
      tended to be arrhythmogenic as evidenced by a general increased frequency of 
      ventricular premature contractions of both single and paired type. Therefore, IN 
      had some hemodynamic efficacy on acute i.v. and p.o. administration but not 
      during chronic therapy, and there was negative safety features of arrhythmias.
FAU - Corder, C N
AU  - Corder CN
AD  - Clinical Pharmacology Division, Oklahoma Medical Research Foundation, Oklahoma 
      City 73104.
FAU - Puls, A
AU  - Puls A
FAU - Wilson, M
AU  - Wilson M
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Int J Clin Pharmacol Ther Toxicol
JT  - International journal of clinical pharmacology, therapy, and toxicology
JID - 8003415
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Diuretics)
RN  - 0 (Indoles)
RN  - 0 (Oxindoles)
RN  - 0 (Pyridazines)
RN  - 0751ZOW7OR (indolidan)
RN  - 73K4184T59 (Digoxin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Cardiotonic Agents/*therapeutic use
MH  - Digoxin/therapeutic use
MH  - Diuretics/therapeutic use
MH  - Drug Therapy, Combination
MH  - Exercise Tolerance/drug effects
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Indoles/pharmacology/*therapeutic use
MH  - Injections, Intravenous
MH  - Middle Aged
MH  - Oxindoles
MH  - Oxygen Consumption
MH  - Pyridazines/pharmacology/*therapeutic use
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther Toxicol. 1992 Oct;30(10):405-9.